Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21291226 | 0.87 | L3MBTL1 (0.44) | L3MBTL1SLC9A3TSHRRECQL | |
| SCHEMBL25344641 | 0.86 | TSHR (0.47) | L3MBTL1EPHX2SLC9A3TSHR | |
| SCHEMBL25344833 | 0.85 | L3MBTL1 (0.41) | L3MBTL1SLC9A3GAA | |
| SCHEMBL24759892 | 0.85 | TSHR (0.43) | L3MBTL1SLC9A3TSHRRECQL | |
| SCHEMBL21290595 | 0.85 | GAA (0.36) | L3MBTL1SLC9A3TSHRGAA | |
| SCHEMBL24588486 | 0.85 | L3MBTL1 (0.45) | L3MBTL1SLC9A3TSHR | |
| SCHEMBL21291271 | 0.82 | TSHR (0.48) | L3MBTL1EPHX2SLC9A3TSHR | |
| SCHEMBL24840970 | 0.82 | L3MBTL1 (0.38) | L3MBTL1SLC9A3TSHR | |
| SCHEMBL21290649 | 0.82 | L3MBTL1 (0.43) | L3MBTL1SLC9A3TSHRGAA | |
| SCHEMBL30980541 | 0.82 | HDAC8 (0.39) | TLR2TLR1EPHX2SLC9A3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | LYCIA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| EP-4370157-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023288033-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | ASGR1, LAMP2, FCGR2A | L3MBTL1 2462/4885TLR2 836/4885TLR1 1983/4885 |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | L3MBTL1 2462/4885TLR2 836/4885TLR1 1983/4885 |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | L3MBTL1 2462/4885TLR2 836/4885TLR1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.